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Abstract
EGFR-targeted therapy in head and neck squamous cell carcinoma (HNSCC) patients frequently 
results in tumor resistance to treatment. Autophagy is an emerging underlying resistance 
mechanism, however, the molecular autophagy machinery in HNSCC cells and potential 
biomarkers of patient response to EGFR-targeted therapy remain insufficiently characterized. Here 
we show that the EGFR blocking with cetuximab leads to varied autophagic responses, which 
modulate cancer cell susceptibility to EGFR inhibition. Inhibition of autophagy sensitizes HNSCC 
cells to EGFR blockade. Importantly, we identify a novel signaling hub centering on the NLRX1-
TUFM protein complex, promoting autophagic flux. Defects in the expression of either NLRX1 or 
TUFM result in compromised autophagy when treated with EGFR inhibitors. As a previously 
undefined autophagy-promoting mechanism, we found that TUFM serves as a novel anchorage 
site, recruiting Beclin-1 to mitochondria, promoting its polyubiquitination, and interfering with its 
interaction with Rubicon. This protein complex is also essential for endoplasmic reticulum (ER) 
stress signaling induction, possibly as an additional mechanism to promote autophagy. Utilizing 
tumor specimens from a novel neoadjuvant clinical trial, we show that increased expression of the 
autophagy adaptor protein, SQSTM1/p62, is associated with poor response to cetuximab therapy. 
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These findings expand our understanding of the components involved in HNSCC autophagy 
machinery that responds to EGFR inhibitors, and suggest potential combinatorial approaches to 
enhance its therapeutic efficacy.
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Introduction
Despite multimodality treatment, the 5-year survival of patients with head and neck 
squamous cell carcinoma (HNSCC) remains at less than 50% 1, 2. A unique biologic 
property of HNSCC is that >90% of these tumors overexpress EGFR, which is pivotal in 
both tumor initiation and maintenance3. Thus in 2006, the FDA approved cetuximab, an 
EGFR monoclonal antibody, for the treatment of advanced or metastatic HNSCC and 
colorectal cancer, which also overexpresses EGFR. Cetuximab shows significant benefit in a 
subset of HNSCC patients, although the response rate is usually below 20% 4, 5. Substantial 
effort has been invested to investigate the potential mechanisms and biomarkers that were 
associated with this treatment. However, neither FcγRIIIa polymorphism of natural killer 
(NK) cells, which affects their binding affinity with cetuximab, nor the EGFR expression or 
gene copy number in tumor cells were associated with HNSCC patient response 3, 6. Overall, 
resistance mechanism associated with EGFR inhibitors remains poorly understood.
One potential contributing resistance mechanism is autophagy, an evolutionarily conserved 
physiologic process that eliminates and recycles excessive protein aggregates and damaged 
organelles to sustain nutrient supply and provides an intrinsic stress-responsive protective 
mechanism 7, 8. Autophagy endows cancer cells with enhanced adaptability to endoplasmic 
reticulum (ER), oxidative, and metabolic stresses 9, 10. Cetuximab promotes autophagy in 
lung cancer cells 11, 12, and strategic inhibition of autophagy could lead to therapeutic 
improvement 10, 11. Also in line with this notion is an observation from a recent clinical trial, 
in which an ER stress- and autophagy- promoting agent bortezomib promoted early tumor 
progression in HNSCC patients when combined with cetuximab 13. However, whether 
autophagy may have an impact on HNSCC cells response to direct EGFR inhibition and 
how EGFR signaling engages autophagy machinery in HNSCC cells remain unanswered 
questions.
We recently discovered a novel autophagy-promoting mitochondrial protein complex that 
relies on “nucleotide-binding, lots of leucine-rich repeats-containing protein member X1” 
(NLRX1) 14, 15. NLRX1 belongs to an evolutionarily conserved NLR family that is potent at 
modulating cell death, inflammation, metabolism, and autophagy pathways 15–19. 
Previously, we found that NLRX1 recruited the autophagy-related (ATG)12–ATG5 
conjugate and ATG16L1 to mitochondria, through an intermediary partner Tu translation 
elongation factor mitochondrial (TUFM). Deficiency in NLRX1 or TUFM protein 
expression resulted in a severe defect in autophagy induction upon viral infection 15. The 
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role of this multimeric protein complex in regulating cancer cell autophagic response is not 
known.
As a signaling converging point of nutrients sensing and intracellular stress signaling, 
autophagy may also synergize with other signaling adaptor molecules to promote 
tumorigenesis. A defect in SQSTM1/p62 expression was shown to impair tumor growth in 
vivo 20, and overexpression of p62 resulted in an increase in xenograft tumor mass 21. In oral 
squamous cell carcinoma, cytoplasmic p62 expression level was significantly higher than 
normal mucosa, and cytoplasmic p62 level positively correlated with LC3B puncta, an 
autophagy induction marker 22. Therefore, we evaluated whether EGFR-targeted therapy 
promoted autophagy and how EGFR signaling blockade engaged the autophagic machinery 
in HNSCC cells. Utilizing unique tumor specimens from a neoadjuvant cetuximab clinical 
trial, we also assessed whether the expression level of p62 was correlated with patient 
response to cetuximab treatment.
Results
EGFR-targeted therapy promoted autophagy in HNSCC cells
First, we screened a series of HNSCC cell lines to assess their autophagic induction upon 
cetuximab treatment. The conversion of LC3B-I to LC3B-II, reflective of autophagic 
induction, was monitored by immunoblot as previously described 15, 23. The relative LC3B-
II level to β-actin loading control was used to quantify autophagy induction. We found that 
cetuximab increased the LC3B-II/β-actin ratio in human papillomavirus (HPV)-negative 
PCI-13 cells and HPV-positive UDSCC2 and SCC90 cells, but autophagy induction in HPV-
negative UMSCC22b cells was modest (Fig. 1A). To rule out the possibility that increased 
LC3B-II might be a result of decreased degradation, we treated two sensitive cell lines 
PCI-13 and UDSCC2 with chloroquine to assess the effect of cetuximab on autophagic flux. 
We found that cetuximab treatment induced autophagic flux in the presence of chloroquine 
(Fig. S1A–B). In order to confirm that the autophagy induction was due to inhibition of 
EGFR signaling, we treated the panel of HNSCC cell lines with an EGFR tyrosine kinase 
inhibitor, gefitinib, and found a similar autophagy induction profile. PCI-13, UDSCC2, and 
SCC90 cells showed increased LC3B-II/β actin ratio, while the autophagic induction in 
UMSCC22b cells was modest (Fig. 1B). As another technique to assess blockade of EGFR 
signaling-initiated autophagy response, we employed confocal imaging analysis. PCI-13 
cells were first transfected with a plasmid expressing EGFP-LC3B 48hrs prior to treatment, 
and then these cells were challenged with cetuximab, gefitinib, or everolimus for 5hrs. 
EGFP-LC3B showed a weak diffuse cytoplasmic staining in the basal state with few 
punctate structure in the cytosol. The formation of LC3B puncta marks the induction of 
autophagy. In PCI-13 cells, cetuximab and gefitinib both induced puncta formation, similar 
to everolimus-treated (positive control) cells (Fig. 1C–D).
Inhibition of autophagy enhances EGFR inhibition-mediated cell growth arrest in HNSCC 
cells
In HNSCC cell lines, treatment with cetuximab alone only had modest to moderate 
inhibitory effects on proliferation in an XTT assay (Fig. 2A–D). These cells showed varied 
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sensitivity to chloroquine, which blocks the acidification of lysosomal compartment and the 
turnover of proteins delivered through autophagosomes. PCI-13, SCC90, and UMSCC22b 
cells appeared to be sensitive to chloroquine treatment alone (Fig. 2A, C, D). Importantly, 
combining chloroquine with cetuximab, which only showed modest effects in suppressing 
cancer cell proliferation, resulted in significantly greater growth inhibition in cells 
displaying autophagy induction upon cetuximab treatment (Fig. 2A–C). In UMSCC22b 
cells, which showed only modest autophagy induction by cetuximab treatment (Fig. 1A), 
combining cetuximab with chloroquine did not show a greater suppression of cancer cell 
proliferation compared to a single agent alone (Fig. 2D).
Although conferring potent autophagy inhibition, chloroquine also interferes with 
autophagy-independent lysosomal functions. In order to specifically interrogate the role of 
autophagy in promoting resistance to EGFR signaling blockade, we employed a recently 
identified, specific and potent autophagy inhibitor spautin-1, which specifically promotes the 
degradation of the Beclin-1-Vps34 autophagy-promoting protein complex 24. PCI-13 and 
UDSCC2 cells, in which autophagy was induced with EGFR signaling blockade, were 
incubated with cetuximab or gefitinib, in the presence or absence of spautin-1. Gefitinib 
alone showed significant inhibitory effect on tumor cell proliferation (Fig 2F, H). Cetuximab 
did not show apparent growth-inhibitory effect when used as a single agent, but EGFR 
inhibitor plus spautin-1 demonstrated significantly stronger suppression of tumor cells 
proliferation than EGFR inhibitors alone (Fig. 2E–H). In addition, by combining spautin-1 
with cetuximab, the clonogenic potential of PCI-13 and UDSCC2 cells was more severely 
compromised than either single agent treatment (Fig. S2A–D).
NLRX1 promotes cetuximab-induced autophagy and ER stress signaling
In order to understand how EGFR signaling blockade promotes autophagy in HNSCC cells, 
we employed a loss-of-function approach to examine the role of a unique mitochondrial 
protein complex. Recently, we discovered that the mitochondrial NLR protein, NLRX1, 
served as a critical tether point to recruit ATG12–ATG5 conjugate and ATG16L1, and 
promoted autophagy in multiple cell types in response to viral insults 14, 15. We investigated 
whether NLRX1 was also pivotal for cetuximab-induced autophagy in HNSCC cells. In 
agreement with our previous finding of its wide tissue and cell type distribution profile 25, 
we found that NLRX1 was expressed by all tested HNSCC cell types. Interestingly, NLRX1 
expression in UMSCC22b cells, which did not show robust autophagic induction upon 
EGFR signaling blockade, was lower compared to the other three tested HNSCC cell lines 
(Fig. 3A). As a confirmatory study, we knocked down the expression of NLRX1 in 
autophagy-inducible PCI-13 cells with a pool of 4 different siRNA sequences targeting 
different regions of NLRX1 mRNA, as previously described 25. Under this condition, a 
severe defect in the generation of LC3B-II was observed in NLRX1-deficient cells compared 
to control cells transfected with a pool of 4 non-targeting siRNA sequences, suggesting that 
NLRX1 was indispensable for cetuximab-induced autophagy (Fig. 3B). To confirm that 
NLRX1 was modulating autophagic flux induced by cetuximab, we treated PCI-13 cells of 
normal or reduced expression level of NLRX1 with chloroquine to block the lysosomal 
degradation of LC3B-II. We showed cetuximab induced autophagic flux, and reduction of 
NLRX1 compromised the conversion of LC3B-I to LC3B-II (Fig. 3B).
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To further understand how NLRX1 engages the autophagy machinery in HNSCC cells, we 
investigated whether NLRX1 promoted cetuximab-induced autophagy through ER stress 
signaling, which has a strong potential in promoting autophagy induction 26. The 
phosphorylation of the eukaryotic initiation factor 2α (eIF2α) marks the induction of ER 
stress signaling and the activation of the unfolded protein response (UPR). We found that 
cetuximab induced the phosphorylation of eIF2α at the serine 51 residue more prominently 
at 5hrs post-treatment (Fig. 3C). Consistently, gefitinib treatment also potently promoted 
UPR as shown by phospoho-eIF2α immunoblotting (Fig. 3D), suggesting that the inhibition 
of the EGFR signaling pathway could trigger an UPR response. Notably, when we knocked 
down NLRX1 in PCI-13 cells, cetuximab-induced phosphorylation of eIF2α was abrogated, 
lending support to the critical role of NLRX1 in ER stress signaling, which serves as an 
underpinning mechanism for autophagy induction.
NLRX1-TUFM complex recruits Beclin-1 to mitochondria, facilitating its polyubiquitination
A recent report of EGFR-associated autophagy suppression showed that active EGFR 
regulates Beclin-1 interactome and promoted its interaction with inhibitors 27. In addition, 
polyubiquitination of Beclin-1 was found to be critical for autophagy induction 28. In two 
recent studies, NLRX1 was found to associate with the E3 ligase TRAF6 29, 30. Thus we 
examined whether the NLRX1-TUFM complex intersects with the Beclin-1 signaling and 
promotes its polyubiquitination in HNSCC cells. First, HA-Beclin-1 plasmid was transfected 
into PCI-13 cells, followed by immunoprecipitation (IP) of HA and immunoblotting of 
endogenous ubiquitin. We found cetuximab treatment promoted the polyubiquitination of 
Beclin-1 (Fig. 4A). Interestingly, upon autophagy induction, Beclin-1 was gradually 
recruited to TUFM, starting as early as 30min post-treatment, and more prominently after 
2hrs (Fig. 4A). In agreement with our previous finding, under the stringent IP and wash 
conditions, we could not detect direct interaction between NLRX1 and Beclin-1 (Fig. 4A). 
To confirm our biochemical results, we performed a co-IP experiment in a completely 
endogenous setting, and recapitulated similar results (Fig. 4B). As the NLRX1-TUFM 
complex resides in mitochondria, we examined whether its interaction with Beclin-1 also 
occurs in mitochondria. Although some co-localization of Beclin-1 to mitochondria was 
seen in non-treated cells, we found more Beclin-1 was temporarily localized to mitochondria 
upon cetuximab treatment (Fig. 4C), suggesting that TUFM may provide a novel anchorage 
site for Beclin-1 to be localized to mitochondria.
TUFM mediates EGFR signaling blockade-induced autophagy and UPR
Since TUFM was found to be a member of the Beclin-1 interactome upon autophagy 
induction, we specifically investigated the function of TUFM in EGFR-mediated autophagy 
modulation. Using the same targeting construct that we previously used 15, we generated a 
lentivirus carrying a turboRFP marker and shRNA targeting TUFM to enforce high 
efficiency gene depletion. We transduced PCI-13 cells with this lentivirus (Fig. 5A), and 
selected the top 20% brightest population to generate a stable TUFM-deficient HNSCC cell 
line. We treated control and TUFM-deficient PCI-13 cells with cetuximab (Fig. 5B) or 
gefitinib (Fig. 5C), and showed that EGFR signaling blockade-induced autophagy as early as 
2hrs post-treatment, and autophagy returned to basal level 24hrs after treatment. A defect in 
TUFM severely compromised autophagy induction by cetuximab or gefitinib, as evidenced 
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by a failure of LC3B-II production (Fig. 5B–C). In the presence of chloroquine, inhibition of 
EGFR signaling using either cetuxiamb or gefitinib promoted autophagic flux, and 
suppression of TUFM expression severely dampened this response (Fig. S3).
Notably, with a phenotype similar to NLRX1-deficient cells, TUFM-deficient cells exhibited 
a dampened UPR upregulation when treated with EGFR signaling inhibitors cetuximab or 
gefitinib (Fig. 5D–E). Considering the involvement of Beclin-1 in EGFR-associated 
autophagy regulation and TUFM-Beclin-1 interaction, we transfected control and TUFM-
deficient cells with HA-Beclin-1, and immunoprecipitated HA-Beclin-1, followed by 
immunoblotting of endogenous ubiquitin. We found that gefitinib, similar to cetuximab, 
promoted the polyubiquitination of Beclin-1, and a reduction of TUFM expression level also 
inhibited the polyubiquitination of Beclin-1 (Fig. 5F). A recent study has revealed that 
EGFR signaling modulates the interaction between Beclin-1 and an inhibitor of autophagy 
Rubicon 27. In order to directly test the hypothesis that whether TUFM regulates autophagy 
by engaging the Beclin-1-Rubicon complex, we immunoprecipitated endogenous Beclin-1 
after challenging PCI-13 cells of normal or reduced expression levels of TUFM with 
gefitinib. In agreement with the previous study 27, we found Rubicon gradually dissociated 
from the Beclin-1 complex through the course of gefitinib treatment, however, such 
dynamics was disturbed when TUFM expression was knocked down despite of comparable 
amount of immunoprecipitated Beclin-1 protein (Fig. 5G). Thus, we identified a novel 
mechanism that regulates EGFR blockade-induced autophagy, namely that NLRX1 and 
TUFM form a mitochondrial protein complex, which mediates UPR signaling, recruits 
Beclin-1, and impedes Beclin-1 interaction with Rubicon, to intersect with autophagy 
machinery in HNSCC cells (Fig. 5H). As an important mechanism that cetuximab employs 
to impose an anti-tumor effect, this mAb engages CD16 on NK cells to promote 
immunogenic cytotoxicity 31, and autophagy has emerged as a critical regulator of tumor 
cell sensitivity to immunogenic attack 32. Thus we reasoned that Beclin-1-TUFM complex 
may promote tumor cell resistance to NK cells through autophagy. We added cetuximab and 
NK cells into the culture of PCI-13 cells with or without expressing shRNA targeting 
Beclin-1 at the tumor : effector (T:E) ratio of 1:10, and incubated for 24hrs. Consistent with 
previous report 32, knocking down Beclin-1 potentiated cetuximab-induced, NK cells-
mediated cytotoxicity (Figure S4A). Similarly, a reduction of TUFM expression also 
resulted increased tumor cell sensitivity to cetuximab-induced immunogenic attack (Figure 
S4B).
SQSTM1/p62 is associated with patient response to cetuximab
Recent evidence showed that cytoplasmic p62 expression correlated with LC3B puncta and 
was higher in oral squamous cell carcinoma than in normal oral mucosa 22. High p62 level 
was also associated with a worse prognosis 22. Thus we interrogated specimens procured 
from a neoadjuvant phase II clinical trial (NCT01218048), in which HNSCC patients were 
administered four weekly doses of cetuximab. Tumor tissue from 23 patients was procured 
before and after treatment. Demographics of enrolled patients are shown in supplementary 
Table 1. Based on our recent study using the same clinical trial material, this sample size is 
sufficient to provide statistically sound conclusions 33. In representative paired tumor 
sections, the p62 expression level post-treatment showed varied response compared to pre-
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treatment specimens (Fig. 6A). Aperio ImageScope quantitation tool was used to determine 
the staining scores of each core, and found that staining for p62 was significantly stronger in 
the post-treatment group (p=0.03) (Fig. 6B). Due to the small size of pre-treatment biopsy 
specimen, not all specimens were paired, and thus overall staining density for p62 was 
analyzed among the whole cohort. In the available paired tumors, p62 staining in the post-
treatment group was also significantly elevated (p=0.04) (Fig. 6C). A head and neck 
radiologist scored paired contrast CT scans pre- and post- neoadjuvant cetuximab treatment 
to evaluate patient tumor burden and objective response to treatment. Notably, in agreement 
with previous work that p62 levels may be a marker for unfavorable prognosis 22, we found 
p62 staining levels were significantly higher after cetuximab treatment among poor clinical 
responders (p=0.03), whereas there was no p62 induction in good clinical responders (Fig. 
6D).
Discussion
In this study, we demonstrated that EGFR-targeted treatment resulted in reproducible 
autophagy induction in some HNSCC cells. A combination of cetuximab or gefitinib with 
inhibitors of autophagy augmented suppression of proliferation in tumor cells with higher 
inducible autophagic response. Importantly, we revealed that NLRX1-TUFM protein 
complex actively recruited Beclin-1 to mitochondria, promoting its polyubiquitination. A 
defect in NLRX1-TUFM protein complex compromised the autophagy induction in cancer 
cells. The clinical importance of these findings was supported by the increased expression of 
the autophagy adaptor p62 among patients who responded poorly to cetuximab treatment, in 
a prospective cohort of HNSCC patients.
The role of autophagy in cancer initiation and treatment has been found to be context-
dependent, because it may engage distinct signaling modules with contrasting functions at 
different stages of tumor initiation and development 9, 11. As evidence has accumulated, 
autophagy appears to serve as a protective mechanism against tumor initiation. However, it 
could endow cancer cells with markedly increased adaptability to metabolic crisis when 
established solid tumors undergo treatment 9, 11. In line with this evidence, the combination 
of cetuximab with an autophagy-promoting agent bortezomib to treat HNSCC patients 
resulted in early disease progression 13. In our study, we showed that a combination of 
autophagy inhibitors, including a specific inhibitor that disrupts Beclin-1-associated Vps34 
complex function, could potentiate EGFR inhibition-mediated growth suppression. This 
finding is also consistent with a recent study, in which non-small-cell lung carcinoma cells 
exhibited increased cell death with less autophagy and decreased cell death with enhanced 
autophagy 27. Another mechanism that underlies the efficacy of cetuximab is it may also 
activate natural killer (NK) cells to launch immunogenic attack against tumor cells, recent 
findings showed autophagy could promote tumor cells resistance to NK-mediated killing 
mechanism 32, suggesting that targeting autophagy may benefit direct sensitization of tumor 
cells to EGFR inhibition and immunogenic killing.
Appreciating the pathologic significance of EGF signaling in many types of solid tumors, 
the mechanisms underlying EGFR inhibition-induced autophagy are rapidly emerging. Two 
groups indicated Beclin-1 and its interactome were involved EGFR-mediated autophagy 
Lei et al. Page 7
Oncogene. Author manuscript; available in PMC 2017 January 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
modulation 27, 34. Active EGFR facilitated the phosphorylation of Beclin-1 and its binding to 
inhibitory molecules 27. In addition, EGFR could also regulate the interaction between 
Beclin-1 and an autophagy inhibitor Rubicon 27. These findings suggest the fundamental 
role of Beclin-1-interacting partners in modulating EGFR-mediated autophagy. In our study, 
we revealed a novel Beclin-1-interacting protein TUFM that promotes autophagy by 
promoting Beclin-1 polyubiquitination and interfering the Beclin-1:Rubicon interaction. 
Beclin-1 could be localized to mitochondria and interact with Bcl-2 and Bcl-xL 35. 
Interestingly, we found that TUFM could gradually associate with Beclin-1 after cetuximab 
treatment, suggesting that TUFM may provide an additional anchorage site for Beclin-1 
mitochondrial localization. Mitochondria were noted to provide membrane for 
autophagosome biogenesis 36. The fact that TUFM associates with both ATG12–ATG5-
ATG16L1 complex and Beclin-1 suggests that TUFM may play an important role in 
promoting autophagosome biogenesis.
In addition to direct biochemical association with Beclin-1 and the ATG12–ATG5 complex, 
we also showed the NLRX1-TUFM complex linked increased intracellular stress to 
autophagy induction. NLRX1 is a unique NLR protein in that it is the only mitochondrial 
protein in this 22-member family. Besides its autophagy-promoting function, NLRX1 was 
also shown to mediate the generation of reactive oxygen species (ROS), and reduction of 
NLRX1 lead to lower ROS level 37. ROS is a potent inducer of autophagy and UPR 
signaling 26. In order to further delineate the mechanism underlying attenuated autophagy 
response in NLRX1-deficient HNSCC cells upon cetuximab challenge, we showed that 
NLRX1 was also essential for UPR activation. Activated UPR signaling could promote 
autophagy in an ATF4-dependent fashion 38. ATF4 is responsible for establishing resistance 
to cetuximab treatment by inducing autophagy in multiple cancers 39–41. Another critical 
target of PERK is eIF2α; and a non-phosphorylatable mutant (S51A) of eIF2α loses its 
capacity in inducing autophagy 42. Our results suggest that NLRX1-TUFM complex could 
employ two different mechanisms, including engaging the Beclin-1 interactome and 
promoting UPR, to modulate cancer cell autophagy response.
Because HNSCC patients’ response rate to cetuximab treatment is low, identification of 
biomarkers that are associated with clinical response may shed light to the development of 
co-targeting strategies. Procurement of specimens before and after cetuximab administration 
uniquely enabled us to assess whether autophagy signaling molecule could be associated 
with objective clinical response in cetuximab treated patients. We showed that tumor from 
poor responders exhibited stronger expression of p62. Although the level of p62 could 
decrease within hours during starvation-induced autophagy, it contains multiple domains 
that could engage complex signaling pathways, and its expression is also regulated by 
transcriptional mechanisms 23. Thus, its expression level over a long period of time is 
confounded by transcriptional regulation. In fact, in several studies, p62 level was also found 
increased with enhanced autophagic flux 43, 44. Further supporting this notion, only a limited 
number of LC3B puncta and lower cytoplasmic p62 was observed in normal oral mucosa, in 
comparison with much more increased LC3B puncta and cytoplasmic p62 staining levels in 
oral squamous cell carcinoma, and a high level of p62 was associated with a poor 
prognosis 22. These results are conceptually consistent with our findings. But we also 
appreciate that p62 has complex functions including tumor growth-regulating potential 
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independent of autophagy-related mechanisms. The poor outcome associated with high p62 
level may be also explained by a pro-survival NF-κB-dependent mechanism that could 
synergize with autophagy to promote tumor growth 20. In addition, p62 could activate a 
protective antioxidant response by engaging the Keap1-Nrf2 signaling pathway and delivers 
resistance to chemotherapy 45. Thus, the efficacy of co-targeting p62 in a cetuximab-based 
regimen warrants future investigation.
In summary, our study showed inhibition of autophagy sensitizes HNSCC cells to EGFR-
targeted treatment, and identified that TUFM, a novel member of the Beclin-1 interactome, 
comprises a novel signaling hub, which connects EGFR inhibition, ER stress signaling, and 
autophagy induction in HNSCC cells. This study represents a conceptual advance in that the 
NLR family, traditionally thought to modulate inflammatory signaling in response to 
microbial challenges, may also directly modulate cancer cell susceptibility to treatment 
through an autophagy-dependent mechanism. Importantly, utilizing clinical HNSCC 
specimens, we found that increased level of the autophagy signaling adaptor p62 was 
associated with an unfavorable objective response. These results provide additional 
molecular candidates for developing potential co-targeting strategies to enhance an EGFR-
targeted therapeutic regimen.
Materials and Methods
Cell culture and treatment
PCI-13, UDSCC2, SCC90, and UMSCC22b cells were maintained in complete DMEM 
medium supplemented with 10% fetal bovine serum (FBS), 4.5g/L glucose, 110mg/L 
sodium pyruvate, 2mM L-glutamine, 1% penicillin and 100μg/ml streptomycin. PCI-13 and 
SCC90 cells were developed and maintained at the University of Pittsburgh. UDSCC2 cells 
were provided by Dr. Henning Bier at the University of Düsseldorf. UMSCC22b was 
generated by Dr. Thomas Carey at the University of Michigan. All cell lines have been 
recently authenticated and tested for mycoplasma contamination. Cetuximab was provided 
by Bristol-Myers Squibb, NYC, NY. Gefitinib was reconstituted in DMSO (Cat. sc-202166, 
Santa Cruz Biotechnology). Everolimus was reconstituted according to manufacturer’s 
instruction (Cat. 07741, Sigma-Aldrich).
RNAi-based protein expression knockdown and plasmid transfection
PCI13 cells were transfected with an ON-TARGETplus SMARTpool of 4 siRNA sequences 
targeting NLRX1 mRNA (Cat. L-012926-01-0005, Dharmacon Research Inc.) or a control 
pool of 4 non-targeting siRNA (Cat. D-001810-10-05, Dharmacon Research Inc.), using 
lipofectamine™ RNAiMax (Cat. 13778-150, Invitrogen). Plasmid expressing EGFP-LC3B 
(human) protein was obtained (Cat. 24920, Addgene), and transfected using PolyFect (Cat. 
301105, Qiagen). In order to generate stable TUFM-deficient PCI-13 cells and non-targeting 
control cells, we purchased TripZ control construct bacteria stock (Cat. RHS4743, Thermo 
Scientific) and sh-TUFM construct bacteria stock (Oligo ID V2THS_222080, Cat. 
RHS4696-99362407, Thermo Scientific). Lentiviruses were packaged as previously 
described 46.
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Western blots and co-immunoprecipitation
Cells were lysed in NP-40-based lysis buffer (1% NP-40, 50mM Tris-HCl pH8.0, 150mM 
NaCl) with freshly added complete protease inhibitor cocktail (Cat. 11873580001, Roche). 
Protein lysates were separated using 15% or 4–12% precast gels (Cat. 58504 and 58522, 
Lonza). The membranes were immunoblotted using the following antibodies: anti-LC3B 
(Cat. 2775, Cell Signaling), anti-NLRX1, anti-eIF2α (Cat. 9722, Cell Signaling), anti-
Phospho-eIF2α (Ser51) (119A11) (Cat. 3597, Cell Signaling), anti-HA-HRP (Cat. 2999, 
Cell Signaling), anti-ubiquitin (Cat. 3936, Cell Signaling), anti-Beclin-1 (Cat. 3495, Cell 
Signaling), anti-p62 (Cat. Ab56416, Abcam), anti-TUFM (Cat. 67991, Abcam), Anti-Mouse 
kappa light chain (HRP) (Cat. ab99632, Abcam), anti-β-Actin (Cat. A5441, Sigma-Aldrich), 
anti-Rabbit IgG (H+L)-HRP Conjugate (Cat. W4011, Promega), and anti-mouse IgG (H+L), 
HRP Conjugate (Cat. 170-6516, Bio-Rad Laboratories). For semi-endogenous co-IP, whole 
cell lysates were incubated with HA-agarose beads (Cat. 26181, Thermo Scientific) at 4°C 
overnight, and then boiled in Laemmli’s buffer at 95°C for 5 min. In the endogenous co-IP 
experiment, whole cell lysates were pre-cleared with protein A/G beads and incubated with 
Beclin-1 antibody overnight. The protein A/G UltraLink resin (Cat. 53132, Thermo 
Scientific) was added on the next day and incubated for 2 hrs. Resin were washed five times 
before boiling in the Laemmli’s buffer.
Laser confocal imaging and colocalization analysis
PCI-13 cells were seeded on glass bottom microwell dishes (Cat. P35GCol-1.5-14-C, 
MatTek) 24hrs prior to transfection with pEGFP-LC3. Two days post-transfection, the cells 
were incubated with cetuximab, gefitinib, or everolimus for 5hrs. Live cells were examined 
under an Olympus FV1000 confocal microscope. The number of puncta per section was 
counted in 40 cells per group and in a total of 200 cells. In the colocalization experiment, 
PCI-13 cells were stained with MitoTracker Deep Red FM (Cat. M22426, Invitrogen) after 
indicated treatments. Cells were then fixed with 3.7% paraformaldehyde in pre-warmed 
complete medium for 15min at 37°C. Fixed cells were permeabilized in 0.2% Triton X-100 
PBS for 15min on a shaker, and stained with anti-HA-Alexa Fluor 488 (Cat. A-21287, Life 
Technologies) overnight. The nuclei were counter-stained with DAPI (Cat. D1306, Life 
Technologies), prior to examination under the laser confocal microscope).
Patient recruitment and TMA analysis
The clinical trial was approved by IRB protocol #: MOD08090382-22/PRO08090382 at the 
University of Pittsburgh, and registered in the ClinicalTrials.gov (NCT01218048). Written 
informed consent was obtained after the nature and potential side effects of this treatment 
were explained to the patients. Patients exclusion criteria include: (1) Eastern Cooperative 
Oncology Group (ECOG) performance status beyond 1, (2) patients below 18 years of age, 
(3) female patients who are pregnant or breastfeeding, and (4) patients who have 
uncontrolled infection and cardiac disease. Tumor specimens prior to and after cetuximab 
treatment were sectioned and evaluated to ensure the tumor mass comprised at least 70% of 
the total potential core area. Two to three cores were extracted from each specimen, and built 
into a tissue microarray (TMA). Immunohistochemical stains were assessed using Aperio 
ImageScope. The staining score was calculated by multiplying staining density and percent 
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of positivity. The pathologist was blinded to the group allocation during the evaluation of the 
cores. Patients’ radiographic response to cetuximab treatment was evaluated by a head and 
neck radiologist.
Statistical Analysis
Comparisons among different treatment groups were made by Kruskal–Wallis one-way 
analysis of variance (ANOVA) followed by Bonferroni multiple comparison tests. 
Comparisons between two groups were made using paired or unpaired t-test. A Bartlett test 
of homogeneity of variances among different groups was performed. Analyses were 
performed using Graphpad Prism 5.0 (Graphpad Software, Inc.). Bar graphs were presented 
as mean ± standard error of mean. A p value of less than 0.05 was considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Inhibition of EGFR signaling promotes autophagy
(A) PCI-13, UDSCC2, SCC90, and UMSCC22b cells were treated with 5.0μg/ml cetuximab 
for the indicated periods of time. Cell lysates were then subjected to SDS-PAGE and 
immunoblotting analysis of LC3B. The expression of β-actin was monitored as a loading 
control. Densitometry was performed using ImageJ. (B) PCI-13, UDSCC2, SCC90, and 
UMSCC22b cells were treated with 12.5μM gefitinib for 5hrs. Cell lysates were 
immunoblotted for LC3B and β-actin to examine autophagy induction. Densitometry was 
analyzed using ImageJ. (C) PCI-13 cells were transfected with EGFP-LC3B plasmids 48 hrs 
prior to treatments. After a visual confirmation of successful transfection of over 90% of 
cells under a fluorescence microscope, cells were then treated with PBS, 5.0μg/ml 
cetuximab, 12.5μM gefitinib, 100nM everolimus, and then examined using laser confocal 
microscopy. (D) Autophagic puncta were counted in one section of 40 cells from each 
group. Comparisons were made by one-way ANOVA followed by Bonferroni post-test.
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Fig. 2. Suppression of autophagy enhances the anti-proliferative effect of EGFR inhibitors in 
HNSCC cells
(A–D) PCI-13, UDSCC2, SCC90, and UMSCC22b cells were treated with cetuximab at 
5.0μg/ml in the presence or absence of 100nM chloroquine. Cell proliferation was 
quantitated by XTT assays 5 days post-treatment. (E–F) PCI-13 cells were treated with 
5.0μg/ml cetuximab or 12.5μM gefitinib in the presence or absence of 10μM spautin-1. (G–
H) UDSCC2 cells were treated by 5.0μg/ml cetuximab or 12.5μM gefitinib with or without 
spautin-1. Cell proliferation was quantitated by XTT assays. Each group contained three 
biological replicates.
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Fig. 3. NLRX1 promotes cetuximab-induced autophagy and ER stress signaling
(A) 1.0×106 non-treated HNSCC cells were lysed for immunoblotting against NLRX1. (B) 
PCI-13 cells were transfected with a pool of 4 NLRX1-targeting or non-targeting siRNAs 72 
hours prior to incubation with 5.0μg/ml cetuximab for 5hrs in the presence or absence of a 2-
hour incubation with 80μM chloroquine. Cell lysates were analyzed for LC3B. (C) PCI-13 
cells were treated with 5.0μg/ml cetuximab and lysed for immunoblotting against the 
indicated ER stress markers. (D) PCI-13 cells were treated with 12.5μM gefitinib and lysed 
for immunoblotting against the indicated proteins. (E) PCI-13 cells were transfected with 
indicated pools of siRNAs, and then treated with cetuximab for immunoblotting of the 
indicated ER stress markers.
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Fig. 4. NLRX1-TUFM complex recruits Beclin-1 to mitochondria, facilitating its 
polyubiquitination
(A) PCI-13 cells were transfected with HA-Beclin-1 plasmid, and treated with cetuximab 
48hrs post-transfection. Cells were lysed and immunoprecipitated with HA-agarose beads, 
which were washed five times and boiled in Laemmli sample buffer. Pre-IP lysate control 
and IP samples were separated by SDS-PAGE and immunoblotted for the indicated proteins. 
(B) PCI-13 cells were lysed and pre-cleared before endogenous Beclin-1 complex was 
immunoprecipitated with protein A/G ultralink beads. Pre-IP input and IP samples were 
processed as described in (A). (C) PCI-13 cells were transfected with HA-Beclin-1 and 
treated with cetuximab for 2hrs and 5hrs, followed by a MitoTracker Deep Red FM staining. 
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Cells were then fixed, permeabilized, and stained with anti-HA-Alexa 488. The nuclei were 
counter-stained with DAPI on the next day prior to imaging. Images were captured using 
laser confocal microscopy.
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Fig. 5. TUFM mediates EGFR signaling blockade-induced autophagy and UPR
(A) PCI-13 cells were transduced with lentiviruses containing a turbo-RFP expressing non-
targeting construct or shRNA targeting TUFM. The brightest 20% cells were sorted out by 
FACS and used to establish stable knockdown cell lines. (B–C) Control and TUFM-deficient 
PCI-13 cells were treated with 5.0μg/ml cetuximab or 2.5μM gefitinib for 2hrs and 24hrs. 
Cell lysates were immunoblotted for LC3B, β-actin, and TUFM. Densitometry was 
performed using ImageJ. (D–E) Control and TUFM-deficient PCI-13 cells were treated with 
cetuximab or gefitinib for 2hrs. Cell lysates were immunoblotted with indicated ER stress 
markers and TUFM for knockdown control. (F) Control or TUFM knockdown PCI-13 cells 
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were treated with 2.5μM gefitinib for 2hrs. Cell lysates were immunoprecipitated with anti-
HA-agarose beads, which were then washed 5 times and boiled in Laemmli sample buffer. 
Pre-IP lysate and IP were immunoblotted against the indicated proteins. (G) PCI-13 cells 
stably expressing shRNA targeting TUFM or control cells were treated with gefitinib for the 
indicated periods of time prior to immunoprecipitation of endogenous Beclin-1. 
Immunoprecipitated proteins were separated by SDS-PAGE, and immunoblotted for 
Rubicon and Beclin-1. Pre-IP lysates were immunoblotted for the indicated control inputs. 
(H) This schematic highlights a novel signaling hub centering on NLRX1-TUFM. Upon 
inhibition of EGFR signaling, TUFM interferes with the interaction between Beclin-1 and 
Rubicon, promotes Beclin-1 polyubiquitination, and induces UPR signaling to modulate 
autophagy. Induction of autophagy in HNSCC cells increases their resistance to EGFR 
inhibitors.
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Fig. 6. SQSTM1/p62 induction is associated with resistance to cetuximab therapy
(A) In our single-agent phase II clinical trial, 4 weekly doses of cetuximab were 
administered in patients with stage III/IV HNSCC. Tumor specimens were procured before 
and after treatment and built into a TMA. Representative pictures from both groups showed 
varied p62 induction. (B) The IHC staining density was analyzed using Aperio ImageScope 
software, and IHC scores were recorded by averaging at least 2 cores from each specimen. 
IHC scores from all patients were recorded and compared between pre-treatment and post-
treatment groups. (C) Only IHC scores of paired specimens from pre-treatment and post-
treatment were compared. (D) Clinical response was evaluated by scoring tumor shrinkage, 
using paired pre- and post- contrast CT scans. The staining density of p62 was assessed in 
tumors from patients who responded favorably and those who responded poorly to 
cetuximab treatment.
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